Payment overview · 2025
General Payments
$291.41
13 reported records · 7 companies
Healthcare provider profile · identity verified
Alexander Merson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1194755983
Verified facts
What the public records show
CMS Open Payments records show Alexander Merson, MD received $291.41 in general payments during 2025 across 13 reported records.
Aimmune Therapeutics, Inc. accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $114.17 | 39.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.83 | 21.6% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $36.05 | 12.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.63 | 7.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.73 | 6.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.03 | 6.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.97 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $291.41 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $114.17 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.83 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $36.05 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 94 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
140 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
128 | 25 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 913 | 150 |
| Metoprolol Succinate | Metoprolol Succinate | 565 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 73 |
| Omeprazole | Omeprazole | 405 | 79 |
| Metformin Hcl | Metformin Hcl | 383 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 317 | 58 |
| Losartan Potassium | Losartan Potassium | 308 | 52 |
| Carvedilol | Carvedilol | 207 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 203 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 31 |
| Doxazosin Mesylate | Doxazosin Mesylate | 178 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 168 | 26 |
| Clonidine Hcl | Clonidine Hcl | 167 | 38 |
| Allopurinol | Allopurinol | 142 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 141 | 25 |
| Linzess | Linaclotide | 140 | 24 |
| Eliquis | Apixaban | 129 | 24 |
| Synthroid | Levothyroxine Sodium | 128 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 23 |
| Buspirone Hcl | Buspirone Hcl | 113 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 21 |
| Ezetimibe | Ezetimibe | 108 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 24 |
| Simvastatin | Simvastatin | 107 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 16 |
| Enalapril Maleate | Enalapril Maleate | 102 | 19 |
| Meloxicam | Meloxicam | 102 | 26 |
| Vascepa | Icosapent Ethyl | 98 | 13 |
| Alendronate Sodium | Alendronate Sodium | 97 | 12 |
| Creon | Lipase/Protease/Amylase | 94 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 69 |
| Famotidine | Famotidine | 90 | 16 |
| Glipizide | Glipizide | 88 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 25 |
| Dexlansoprazole Dr | Dexlansoprazole | 79 | 13 |
| Gabapentin | Gabapentin | 79 | 13 |
| Januvia | Sitagliptin Phosphate | 78 | 17 |
| Celecoxib | Celecoxib | 77 | 28 |
| Benazepril Hcl | Benazepril Hcl | 74 | 11 |
| Lisinopril | Lisinopril | 74 | 17 |
| Metformin Hcl Er | Metformin Hcl | 67 | 11 |
| Repatha Sureclick | Evolocumab | 67 | suppressed |
| Jardiance | Empagliflozin | 66 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 13 |
| Farxiga | Dapagliflozin Propanediol | 56 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Valsartan | Valsartan | 50 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | suppressed |
| Telmisartan | Telmisartan | 48 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 12 |
| Ozempic | Semaglutide | 45 | suppressed |
| Ranolazine Er | Ranolazine | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 43 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 43 | suppressed |
| Finasteride | Finasteride | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 39 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 37 | 16 |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Repatha Syringe | Evolocumab | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | 11 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Furosemide | Furosemide | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 28 |
| Montelukast Sodium | Montelukast Sodium | 31 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Proctozone-Hc | Hydrocortisone | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 12 |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Procto-Med Hc | Hydrocortisone | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $291.41 · 13 records | Aimmune Therapeutics, Inc. | ACCRUFER, CREON, FARXIGA, OTEZLA, Ozempic, REPATHA, Rybelsus, TZIELD, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error